AstraZeneca: Tezepelumab Trial Didn't Meet Primary Endpoint
22 Dezember 2020 - 8:53AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Tuesday that the 48-week Phase 3 trial of
the potential new medicine tezepelumab--aimed at treating severe
asthma--didn't meet the primary endpoint.
The British-Swedish pharmaceutical major said the trial didn't
show a "statistically significant reduction in the daily use of
oral corticosteroids without loss of asthma control, with
tezepelumab compared to placebo."
The initial analysis of the trial indicates that its design
might have contributed to the outcome of the primary endpoint,
adding that it is analyzing the data to share the results, the
FTSE-100 listed company said.
"We remain confident that tezepelumab has the potential to
improve care for a broad population of severe asthma patients,"
Mene Pangalos, executive vice president of biopharmaceuticals
research and development, said.
The safety profile of the medicine in the trial was consistent
with previous trials, AstraZeneca added.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 22, 2020 02:38 ET (07:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024